Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kipps, Thomas J. [1 ]
Swinnen, Lode J. [2 ]
Wierda, William G. [3 ]
Jones, Jeffrey Alan [4 ]
Coutre, Steven E. [5 ,6 ,7 ]
Smith, Mitchell R. [8 ]
Yang, Jainning [9 ]
Cui, Yue [9 ]
Busman, Todd [9 ]
Enschede, Sari [9 ]
Humerickhouse, Rod [9 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Johns Hopkins Univ, Sch Med, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[4] Ohio State Univ, Columbus, OH 43210 USA
[5] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA
[6] Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA
[7] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[8] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[9] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1669 / 1669
页数：1
相关论文
共 50 条
  • [21] An Ongoing Phase 1 Study of ABT-263; Pharmacokineties, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
    Roberts, Andrew W.
    Brown, Jennifer
    Seymour, John F.
    Wierda, William G.
    Kipps, Thomas J.
    Xiong, Hao
    Chiu, Yi-Lin
    Busman, Todd
    Knight, Raymond A.
    Enschede, Sari
    Krivoshik, Andrew
    Humerickhouse, Rod
    BLOOD, 2008, 112 (11) : 1089 - 1090
  • [22] EFFICACY OF THE COMBINATION OF BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Zagoskina, T.
    Zotina, E.
    Ovsepyan, V.
    Shardakov, V.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [23] Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).
    Fischer, Kirsien
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Renschler, Jasmin
    Busch, Raymonde
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael
    Fink, Anna M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Staib, Peter
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2007, 110 (11) : 913A - 914A
  • [24] Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Busch, Raymonde
    Renschler, Jasmin
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael J.
    Fink, Anna-Maria
    Kilp, Julia
    Ritgen, Matthias
    Boettcher, Sebastian
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    BLOOD, 2008, 112 (11) : 128 - 128
  • [25] Combined chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for relapsed or untreated progressive chronic lymphocytic leukemia (CLL). A single center experience.
    Pavlovsky, S
    Pavlovsky, C
    Pardo, L
    Sapia, S
    Fernandez, II
    Juni, M
    BLOOD, 2005, 106 (11) : 340B - 340B
  • [26] PHASE 1/2A STUDY OF NAVITOCLAX (ABT-263) IN RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES
    Wilson, H.
    O'Connor, A.
    Czuczman, S.
    LaCasce, S.
    Gerecitano, F.
    Leonard, P.
    Tulpule, A.
    Xiong, H.
    Chiu, Y. L.
    Busman, T.
    Enschede, H.
    Krivoshik, P.
    Humerickhouse, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 116 - 117
  • [27] Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [29] Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies
    Kahl, Brad
    Roberts, Andrew W.
    Seymour, John F.
    Advani, Ranjana H.
    Persky, Daniel Oscar
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1608 - 1608
  • [30] ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Phillip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2849 - +
12345